Early Postnatal Dexamethasone Therapy for the Prevention of Chronic Lung Disease in Preterm Infants With Respiratory Distress Syndrome: A Multicenter Clinical Trial

Abstract

ABSTRACT. Objectives. To study whether early postnatal (<12 hours) dexamethasone therapy reduces the incidence of chronic lung disease in preterm infants with respiratory distress syndrome.Materials and Methods. A multicenter randomized, double-blind clinical trial was undertaken on 262 (saline placebo, 130; dexamethasone, 132) preterm infants (<2000 g) who had respiratory distress syndrome and required mechanical ventilation shortly after birth. The sample size was calculated based on the 50% reduction in the incidence of chronic lung disease when early dexamethasone is used, allowing a 5% chance of a type I error and a 10% chance of a type II error. For infants who received dexamethasone, the dosing schedules were: 0.25 mg/kg/dose every 12 hours intravenously on days 1 through 7; 0.12 mg/kg/dose every 12 hours intravenously on days 8 through 14; 0.05 mg/kg/dose every 12 hours intravenously on days 15 through 21; and 0.02 mg/kg/ dose every 12 hours intravenously on days 22 through 28. A standard protocol for respiratory care was followed by the participating hospitals. The protocol emphasized the criteria of initiation and weaning from mechanical ventilation. The diagnosis of chronic lung disease based on oxygen dependence and abnormal chest roentgenogram was made at 28 days of age. To assess the effect of dexamethasone on pulmonary inflammatory response, serial tracheal aspirates were assayed for cell counts, protein, leukotriene B 4 , and 6-keto prostaglandin F 1␣ . All infants were observed for possible side effects, including hypertension, hyperglycemia, sepsis, intraventricular hemorrhage, retinopathy of prematurity, cardiomyopathy, and alterations in calcium homeostasis, protein metabolism, and somatic growth.Results. Infants in the dexamethasone group had a significantly lower incidence of chronic lung disease than infants in the placebo group either judged at 28 postnatal days (21/132 vs 40/130) or at 36 postconceptional weeks (20/132 vs 37/130). More infants in the dexamethasone group than in the placebo group were extubated during the study. There was no difference between the groups in mortality (39/130 vs 44/132); however, a higher proportion of infants in the dexamethasone group died in the late study period, probably attributable to infection or sepsis. There was no difference between the groups in duration of oxygen therapy and hospitalization. Early postnatal use of dexamethasone was associated with a significant decrease in tracheal aspirate cell counts, protein, leukotriene B 4 , and 6-keto prostaglandin F 1␣ , suggesting a suppression of pulmonary inflammatory response. Significantly more infants in the dexamethasone group than in the placebo group had either bacteremia or clinical sepsis (43/132 vs 27/130). Other immediate, but transient, side effects observed in the dexamethasone group are: an increase in blood glucose and blood pressure, cardiac hypertrophy, hyperparathyroidism, and a transient delay in the rate of growth.Conclusions. In preterm infants with severe respiratory distress syn...

Emerging trends in acquired neonatal intestinal disease: is it time to abandon Bell's criteria?

“…From these data some individuals suggested that the prevalence of SIP was so small that additional trials of early postnatal steroids were warranted for risk versus benefit analyses. 38 For the purpose of this paper, the NNH was calculated comparing all studies to date that used an a priori definition, 33,39 -43 versus those without, 32,[34][35][36][37][44][45][46] to illustrate the disturbing impact of this reporting bias ( Figure 2). With an a priori definition, for every 16 infants receiving postnatal steroids, one developed SIP.…”

Contribution of early glycemic status in the development of severe retinopathy of prematurity in a cohort of ELBW infants

“…1,9,10 However, there is no evidence demonstrating a direct cause-effect relationship. The lack of an accepted severity of illness score for newborns after the first 24 h of life 11 complicates interpretation of the data, as glucose instability can be an expression of severity of illness, 12,13 which may be the risk factor for ROP.…”

Dexamethasone Exposure of Neonatal Rats Modulates Biliary Lipid Secretion and Hepatic Expression of Genes Controlling Bile Acid Metabolism in Adulthood Without Interfering With Primary Bile Acid Kinetics

“…Glucocorticoids (GC) are widely used in immature newborns because of their anti-inflammatory effects (7). Increasing evidence indicates that GC administration in early life may have long-term effects, including growth retardation (8), cardiac dilatation, and cardiac hypertrophy (9).…”